Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1419621

A Dual-Radiomics Model for Overall Survival Prediction in Early-Stage NSCLC Patient Using Pre-Treatment CT Images

Provisionally accepted
Rihui Zhang Rihui Zhang 1Haiming Zhu Haiming Zhu 1*Minbin Chen Minbin Chen 2Weiwei Sang Weiwei Sang 1*Ke Lu Ke Lu 3*Zhen Li Zhen Li 4Chunhao Wang Chunhao Wang 3Lei Zhang Lei Zhang 1Fangfang Yin Fangfang Yin 1Zhenyu Yang Zhenyu Yang 1*
  • 1 Duke Kunshan University, Kunshan, China
  • 2 First People's Hospital of Kunshan, Kunshan, Jiangsu, China
  • 3 Department of Radiation Oncology, School of Medicine, Duke University, Durham, North Carolina, United States
  • 4 Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Radiation therapy (RT) is one of the primary treatment options for early-stage non-small cell lung cancer (ES-NSCLC). Therefore, accurately predicting the overall survival (OS) rate following radiotherapy is crucial for implementing personalized treatment strategies. This work aims to develop a dual-radiomics (DR) model to (1) predict 3-year OS in ES-NSCLC patients receiving RT using pretreatment CT images, and (2) provide explanations between feature importance and model prediction performance. The publicly available TCIA Lung1 dataset with 132 ES-NSCLC patients received RT were studied: 89/43 patients in the under/over 3-year OS group. For each patient, two types of radiomic features were examined: 56 handcrafted radiomic features (HRFs) extracted within gross tumor volume, and 512 image deep features (IDFs) extracted using a pre-trained U-Net encoder. They were combined as inputs to an explainable boosting machine (EBM) model for OS prediction. The EBM's mean absolute scores for HRFs and IDFs were used as feature importance explanations. To evaluate identified feature importance, the DR model was compared with EBM using either (1) key or (2) non-key feature type only. Comparison studies with other models, including supporting vector machine (SVM) and random forest (RF), were also included. The performance was evaluated by the area under the receiver operating characteristic curve (AUCROC), accuracy, sensitivity, and specificity with a 100-fold Monte Carlo cross-validation. The DR model showed highest performance in predicting 3-year OS (AUCROC=0.81±0.04), and EBM scores suggested that IDFs showed significantly greater importance (normalized mean score=0.0019) than HRFs (score=0.0008). The comparison studies showed that EBM with key feature type (IDFs-only) demonstrated comparable AUCROC results (0.81±0.04), while EBM with non-key feature type (HRFs-only) showed limited AUCROC (0.64±0.10). The results suggested that feature importance score identified by EBM is highly correlated with OS prediction performance. Both SVM and RF models were unable to explain key feature type while showing limited overall AUCROC=0.66±0.07 and 0.77±0.06, respectively. Accuracy, sensitivity, and specificity showed a similar trend. In conclusion, a DR model was successfully developed to predict ES-NSCLC OS based on pre-treatment CT images. The results suggested that the feature importance from DR model is highly correlated to the model prediction power.

    Keywords: Early-stage non-small cell lung cancer, overall survival, Explainable AI, Radiomics, deep learning, radiation therapy

    Received: 18 Apr 2024; Accepted: 26 Jul 2024.

    Copyright: © 2024 Zhang, Zhu, Chen, Sang, Lu, Li, Wang, Zhang, Yin and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Haiming Zhu, Duke Kunshan University, Kunshan, China
    Weiwei Sang, Duke Kunshan University, Kunshan, China
    Ke Lu, Department of Radiation Oncology, School of Medicine, Duke University, Durham, 27710, North Carolina, United States
    Zhenyu Yang, Duke Kunshan University, Kunshan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.